Actively Recruiting
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Led by Verastem, Inc. · Updated on 2026-04-22
295
Participants Needed
14
Research Sites
179 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.
CONDITIONS
Official Title
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years of age or older
- Signed informed consent form approved by an ethics committee
- Histologic or cytologic evidence of locally advanced unresectable or metastatic solid tumor with KRAS G12D mutation
- Measurable disease based on RECIST v1.1 criteria
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Adequate organ and cardiac function
- Recovery from all side effects of previous therapies to Grade 1 or baseline
- Agreement to use highly effective contraception
You will not qualify if you...
- Major surgery within 4 weeks before starting treatment, except for diagnostic procedures
- Chemotherapy, targeted therapy, or radiotherapy (except palliative radiation) within 4 weeks or 5 half-lives before treatment start
- Immunotherapy within 4 weeks before treatment start
- Participation in other investigational drug treatments within 4 weeks or 5 half-lives before treatment
- Previous treatment with direct and specific KRAS G12D inhibitors
- Symptomatic, untreated, or actively progressing central nervous system metastases
- Inability to swallow oral medications
- History or evidence of uncontrolled serious medical conditions including hematologic, renal, hepatic, endocrine, pulmonary, gastrointestinal, cardiovascular, psychiatric, coagulation, neurologic, dermatologic, autoimmune, or allergic diseases
- Pregnancy or breastfeeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 14 locations
1
Cedars-Sinai Medical Center
Los Angeles, California, United States, 90048
Actively Recruiting
2
Johns Hopkins University
Baltimore, Maryland, United States, 21287
Actively Recruiting
3
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Actively Recruiting
4
University of Michigan
Ann Arbor, Michigan, United States, 48109
Actively Recruiting
5
Washington University School of Medicine
St Louis, Missouri, United States, 63110
Actively Recruiting
6
Laura & Isaac Perlmutter Cancer Center at NYU Langone
New York, New York, United States, 10016
Actively Recruiting
7
Univ of Pennsylvania, Abramson Cancer Center
Philadelphia, Pennsylvania, United States, 19104
Actively Recruiting
8
SCRI Oncology Partners
Nashville, Tennessee, United States, 37203
Actively Recruiting
9
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
10
Huntsman Cancer Institute
Salt Lake City, Utah, United States, 84112
Actively Recruiting
11
University of Virginia
Charlottesville, Virginia, United States, 22908
Actively Recruiting
12
Virginia Cancer Specialists
Fairfax, Virginia, United States, 22031
Actively Recruiting
13
Virginia Mason Medical Center
Seattle, Washington, United States, 98101
Actively Recruiting
14
Peninsula and Southeast Oncology
Frankston, Victoria, Australia, 3199
Actively Recruiting
Research Team
V
Verastem Call Center
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
10
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here